^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    5d
    Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial. (PubMed, Commun Med (Lond))
    Our findings highlight the potential of epigenetic modulators to re-shape the tumor microenvironment of PROC toward a more inflammed phenotype and may point to approaches to augment immunotherapy response.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Platinum resistant
    |
    CD8 (cluster of differentiation 8) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab) • Onureg (azacitidine oral)
    5d
    Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab)
    12d
    A Single-Arm Prospective Clinical Study of Senaparib as First-Line Maintenance Treatment in HRD-Negative Advanced Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ChiCTR2600117429)
    P=N/A, N=60, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen Universit
    New trial
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Paishuning (senaparib)
    12d
    Study on the Correlation Between Mutation Types of BRCA Gene-Positive Epithelial Ovarian Cancer and Clinical Baseline Characteristics, Pathological Features, and Prognosis (ChiCTR2600116755)
    P=N/A, N=80, Not yet recruiting, Linyi Tumor Hospital; Linyi Tumor Hospital
    New trial
    |
    BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    12d
    A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ChiCTR2600117526)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Paishuning (senaparib)
    12d
    Iparomlimab and tuvonralimab (QL1706) with chemotherapy as neoadjuvant therapy for advanced ovarian cancer, fallopian tube, primary peritoneal cancer with high CD8+ tumor infiltrating lymphocytes (TILs) (ChiCTR2500113846)
    P2, N=35, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    CD8 (cluster of differentiation 8)
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    12d
    A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR2500112955)
    P2, N=30, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan) • Lucentis (ranibizumab)
    13d
    Diet, Hepcidin, and Chemotherapy RDI (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, George Washington University | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (clinicaltrials.gov)
    P2, N=10, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion • HEOR
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin
    15d
    Clinical and Prognostic Relevance of BRIP1 Expression in Colorectal Cancer: Evidence from TCGA and Korean Cohorts. (PubMed, Medicina (Kaunas))
    Lower BRIP1 mRNA expression is significantly associated with aggressive clinicopathological features and poor prognosis in CRC. BRIP1 may serve as a promising biomarker for risk stratification and a potential therapeutic target in the management of CRC.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • CEACAM5 (CEA Cell Adhesion Molecule 5) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
    |
    BRIP1 mutation
    19d
    Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life (clinicaltrials.gov)
    P=N/A, N=74, Not yet recruiting, Taipei Veterans General Hospital, Taiwan
    New trial • HEOR
    19d
    Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset. (PubMed, J Gynecol Oncol)
    The HALO-Taiwan was the first observational study reporting HRD prevalence of 52.9% among patients with advanced OC in Taiwan. Our findings underscore the need to implement guideline-recommended testing for HRD as a part of the initial diagnostic work-up for all newly-diagnosed advanced high-grade OC patients to optimize treatment strategies.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • BRCA mutation